HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
The FDA approved Trutakna, a kidney disease drug from Vera Therapeutics, for treating IgA nephropathy at an annual price of $425,000. U.K. officials are finalizing a pricing deal with AstraZeneca and Daiichi Sankyo to provide access to Enhertu, a breast cancer drug previously deemed too costly for the U.K. market.
Mentioned
Related Signal
Adjacent reporting
- STAT+: FDA approves Vera Therapeutics kidney disease treatment
- Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
- STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more